Articles tagged with Clinical Trials
A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.
The D-CARE study found no differences in patient behavioral symptoms or caregiver strain between health system and community-based care approaches. However, comprehensive care improved caregiver self-efficacy, which remained consistent throughout the 18-month period.
A new phase 2 clinical trial demonstrates the safety of fecal microbiota transplantation (FMT) in preventing acute graft-versus-host disease in patients undergoing allogeneic stem cell transplants. The study found that FMT helped restore microbial diversity and promote beneficial bacterial species, supporting a healthy immune system.
A new trial will test whether taking HMB can improve patients' physical function and quality of life. The BOOST study aims to recruit 124 patients with cirrhosis and measure its effects on liver disease, mental wellbeing, and physical function over 24 weeks.
Researchers have found that surgical lung volume reduction (LVRS) for advanced emphysema patients offers better outcomes than previously reported, including lower mortality rates and fewer procedure-related complications. In contrast, endobronchial valve (EBV) placement was associated with higher occurrences of complications over time.
A blood test using Signatera detected tiny fragments of tumor DNA in the blood, which showed that adding celecoxib to treatment may improve disease-free survival for patients with stage III colon cancer. The analysis found significantly improved outcomes for those taking celecoxib compared to placebo.
A blood test detecting circulating tumor DNA (ctDNA) can predict stage 3 colon cancer patients' risk of recurrence. Adding anti-inflammatory drug celecoxib to post-surgery treatment improves disease-free survival for those with positive ctDNA tests.
A phase III trial found that combining radiotherapy with cetuximab improved disease-free survival in patients with HPV-negative head and neck cancer, but not overall survival. The treatment was also associated with higher rates of acute toxicity.
Researchers call for special ethical care as neural implants improve mobility and alleviate pain for patients with neurological disorders. However, concerns over data protection, psychological privacy and hacker risks pose significant challenges to the development of these technologies.
University of Oklahoma Health Sciences is part of a new NIH program integrating clinical research into primary care practices in medically underserved areas. The program aims to increase access to vital health care and speed up the adoption of new evidence-based guidelines.
Insilico Medicine has successfully dosed the first patient in its global Phase I clinical trial of ISM6331, a potent pan-TEAD inhibitor. The treatment demonstrates superior efficacy and safety in preclinical studies, with potential synergistic anti-tumor effects and overcoming drug resistance.
A research team from the University of Minnesota Medical School received a $1.2 million grant to study the use of TMS in addition to CBIT as a treatment for children with Tourette syndrome. The trial found that this new treatment improved brain circuits involved in tics, and the researchers hope it could lead to a future treatment option.
Despite decreased aspirin use among adults with low and higher ASCVD risk, many patients with limited benefit to treatment continue taking aspirin. The study highlights the need for better understanding of individual risk factors to improve treatment decisions.
A study demonstrates the effectiveness of telephone-delivered acceptance and commitment therapy in reducing fatigue's interference with functioning and improving quality of life for metastatic breast cancer survivors. The remote intervention showed promise in reducing sleep interference, leading to improved sleep quality and a greater ...
Researchers found that short-course antibiotics can be as effective as traditional longer treatments in preventing death and recurrence of pneumonia. This approach offers significant value for healthcare systems by reducing hospital expenditure while maintaining excellent patient outcomes.
A 12-week randomized controlled trial found that IDPN using ENEFLUID increased energy intake from food and reduced hypoglycemia during dialysis, suggesting potential benefits for malnourished hemodialysis patients. However, the study did not demonstrate direct improvements in nutritional markers.
The study, published in the Journal of Clinical Oncology, showed no significant difference in patient survival between two-drug and three-drug chemotherapy regimens. The researchers found that the three-drug regimen may increase toxicity but could be a viable option for specific patients with certain types of biliary tract cancers.
The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.
A new trial has found that patients with suspected invasive bladder cancer treated with initial MRI imaging and biopsy are faster than those assessed with TURBT alone. The BladderPath trial showed a median time of 53 days from referral to correct treatment, compared to 98 days for usual care.
A large UK trial found that adding procalcitonin (PCT) to routine care did not reduce IV antibiotic use in hospitalized children. The study, part of the BATCH trial, enrolled nearly 2,000 children and tested PCT's effectiveness in guiding treatment decisions.
The ePRO monitoring system significantly improved patient-physician communication and treatment explanations, supporting patient-centered cardiovascular care. The study found that the system's implementation enhanced patient outcomes and reduced healthcare disparities.
A new tablet combining albendazole and ivermectin is safe and more effective than albendazole alone in treating Trichuris trichiura and other soil-transmitted helminths. The ALIVE clinical trial showed higher cure rates for T. trichiura, hookworms, and improved egg reduction rates compared to albendazole alone.
The project aims to improve the design of clinical trials for neurological conditions like stroke, Parkinson's disease, and vascular cognitive impairment and dementia. Community partners will facilitate academic and community partnerships for clinical trial development.
A groundbreaking UK study found that using procalcitonin (PCT) to guide treatment decisions did not reduce antibiotic duration in hospitalized children. The PCT test was safe but costlier than standard methods, and healthcare teams faced challenges integrating it into their decision-making processes.
A new AI platform, TrialTranslator, helps clinicians and patients assess individual patient benefits from clinical trials by analyzing real-world data. The study reveals that machine learning can identify groups of patients in whom randomized controlled trial results are less generalizable.
A new study aims to address pain treatment disparities by empowering Black patients with chronic pain and depression to find safe, effective approaches. The EQUIPD intervention uses individual coaching to help patients work through different non-medication treatment options.
A new type of bioengineered blood vessel demonstrated superior infection resistance and better limb preservation compared to conventional synthetic grafts. The technology has the potential to reduce amputation numbers significantly, as it can be implanted immediately and is more resistant to infection than traditional options.
A systematic literature search identified high-priority clinical actions for post-acute care, including early education, risk assessment, and mental health screening. Implementing these actions can improve the quality of care for non-hospitalized TBI patients.
Researchers are investigating a water vapor system that uses small, targeted amounts of steam to kill cancer cells in patients with intermediate-risk prostate cancer. The trial aims to explore the safety and effectiveness of this treatment as an alternative to traditional therapies, which can cause life-altering side effects.
The alliance aims to generate evidence supporting national guideline inclusion and healthcare provider adoption of Myriad's Precise MRD test. The studies will explore the test's utility in breast, gastrointestinal, genitourinary and gynecological cancers.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Engaging in 30 minutes of aerobic exercise per week modestly reduces body weight, waist circumference, and body fat measures. Aerobic training exceeding 150 minutes per week may be needed for clinically important reductions.
A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.
Researchers at Vanderbilt University have successfully completed a phase I clinical trial of VU319, a drug that increases the efficacy of acetylcholine at the M1 receptor, showing promise as an Alzheimer's treatment. The trial demonstrated no side effects and target engagement at the highest dose tested.
A clinical trial showed that an antibody blocking Nogo-A protein improves motor function in patients with incomplete spinal cord injuries. The treatment led to significant improvements in voluntary muscle activation and everyday life functional independence. Further studies are needed to confirm the findings.
A randomized clinical trial found that a brief outpatient rehabilitation program improved physical function in patients with post-COVID condition. The intervention showed sustained benefits over time, with negligible adverse effects.
People with severe depression who received vagus nerve stimulation showed significant improvement in depressive symptoms, quality of life, and ability to complete everyday tasks after a year. Despite this, the therapy remains unaffordable for many patients due to high costs.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
EBViously aims to prevent infectious mononucleosis and secondary diseases such as ME/CFS, while also protecting against certain types of cancer. The company's innovative vaccine candidate uses virus-like particles derived from EBV to trigger a targeted immune response.
A phase 1/2 clinical trial has demonstrated the safety and effectiveness of the AEF0217 molecule in improving cognitive function in people with Down syndrome. Measured outcomes showed significant improvements in behavioral skills, social interactions, and cognitive flexibility.
The Keck School of Medicine of USC has joined the Ryght Research Network to leverage AI tools and optimize cancer clinical trials. The collaboration aims to offer more clinical trials to patients, build new AI tools, and speed up the development of medical treatments.
This randomized clinical trial suggests that transcutaneous auricular vagus nerve stimulation is a safe and effective treatment option for chronic insomnia. Future multicenter trials are needed to validate its effectiveness across different populations.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
A randomized clinical trial found that cannabidiol (CBD) significantly reduced anxiety levels 2-4 hours after ingestion in women with advanced breast cancer. CBD's anxiolytic effect suggests its potential as a treatment for scan-related anxiety.
The ZEST trial found that patients with detectable circulating tumor DNA (ctDNA) were more likely to have aggressive disease characteristics. To improve outcomes, researchers recommend starting ctDNA testing during treatment rather than waiting for completion, and targeting high-risk patients with tailored therapies.
Researchers from Kessler Foundation will evaluate the efficacy of Brain.Q's 'Q Therapeutic System' in a two-year study. The therapy involves electromagnetic stimulation and low-intensity fields to optimize brain adaptation and healing after stroke.
Women with low-risk ductal carcinoma in situ reported similar experiences undergoing active monitoring versus guideline-concordant care. The study found that both approaches had comparable lived experiences during the 2-year follow-up period.
The PATINA study demonstrates that palbociclib improves progression-free survival (PFS) in patients with HR+, HER2+ metastatic breast cancer, with a median PFS of 44.3 months. This represents an extension in median PFS of over 15 months compared to anti-HER2 therapy and endocrine therapy alone.
Insilico Medicine has received its first clinical milestone payment of $10 million from Exelixis for XL309, a selective USP1 inhibitor discovered with the company's AI platform. The drug is being developed for advanced solid tumors and has shown efficacy in preclinical studies.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
Researchers found no correlation between adenotonsillectomies and undesirable weight gain in children with mild sleep-disordered breathing. The study used data from a clinical trial involving 458 children and showed that adenotonsillectomy improved symptoms, blood pressure, and quality of life but not primary neurodevelopmental outcomes.
The OlympiA trial found that olaparib significantly improves survival outcomes in patients with high-risk, BRCA-positive breast cancer. After a median follow-up of 6.1 years, patients treated with olaparib showed better rates of invasive and distant disease-free survival compared to those who received placebo.
A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.
A new treatment shows promise for people with high-risk smoldering multiple myeloma, delaying cancer progression and improving overall survival. Daratumumab significantly reduces risk of progression to active disease and improves patient outcomes.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat was safe but did not improve mpox resolution or pain in adults with mild to moderate clade II mpox. The study recommended stopping further enrollment due to the lack of efficacy signal.
A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.
Dr. Aditya Bardia's appointment as Editor-in-Chief of Breast Cancer Research and Treatment reflects his expertise in targeted therapies and innovative research. He aims to foster innovation and disseminate knowledge benefiting patients and the scientific community through this journal.
A large clinical trial found that removing 10% of a patient's blood before major liver surgery reduces the need for transfusions by half. This practice, known as hypovolemic phlebotomy, lowers blood pressure in the liver and is safe, simple, and inexpensive.